Richard Body1, Gillian Burrows2, Simon Carley3, Louise Cullen4, Martin Than5, Allan S Jaffe6, Philip S Lewis2. 1. The University of Manchester, Oxford Road, Manchester, UK; Central Manchester University Hospitals Foundation NHS Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK; richard.body@manchester.ac.uk. 2. Stockport NHS Foundation Trust, Poplar Grove, Stockport, UK; 3. Central Manchester University Hospitals Foundation NHS Trust, Manchester Academic Health Science Centre, Oxford Road, Manchester, UK; Manchester Metropolitan University, Hathersage Road, Manchester, UK; 4. Royal Brisbane and Women's Hospital, Brisbane, Australia; 5. University of Otago, Christchurch, New Zealand; 6. Mayo Clinic and Mayo College of Medicine, Rochester, MN.
Abstract
BACKGROUND: Initial reports suggest that concentrations of high-sensitivity cardiac troponin T (hs-cTnT) (Roche Diagnostics Elecsys(®)) below the limit of blank (LoB) (3 ng/L) or limit of detection (LoD) (5 ng/L) of the assay have almost 100% negative predictive value (NPV) for acute myocardial infarction (AMI), particularly among patients without electrocardiograph (ECG) evidence of ischemia. We aimed to prospectively validate those findings. METHODS: We included adults presenting to the emergency department with suspected cardiac chest pain. Standard troponin T (cTnT) and hs-cTnT (both Roche Elecsys) were tested in samples drawn on arrival. The primary outcome was AMI, adjudicated by 2 investigators on the basis of clinical data and ≥12-h cTnT testing. We also evaluated diagnostic performance when AMI was readjudicated on the basis of hs-cTnT (≥12-h) concentrations. RESULTS: Of 463 patients included, 79 (17.1%) had AMI. Twenty-four patients (5.2%) had hs-cTnT concentrations below the LoB, although none had AMI. Ninety-six patients (20.7%) had hs-cTnT concentrations below the LoD, 1 of whom had AMI. Thus, diagnostic sensitivity was 98.7% (95% CI 87.5%-98.6%) and NPV was 99.0% (95% CI 94.3%-100.0%). Of the 17.3% (n = 80) patients with hs-cTnT below the LoD and no ECG ischemia, none had AMI. Thus, diagnostic sensitivity was 100.0% (95% CI 95.4%-100.0%) and NPV was 100.0% (95% CI 95.5%-100.0%). Sensitivity and NPV were maintained when AMI was readjudicated on the basis of hs-cTnT. CONCLUSIONS: Our findings confirm that patients with nonischemic ECG and undetectable hs-cTnT at presentation have a very low probability of AMI, although the proportion of patients affected was smaller than in previous research.
BACKGROUND: Initial reports suggest that concentrations of high-sensitivity cardiac troponin T (hs-cTnT) (Roche Diagnostics Elecsys(®)) below the limit of blank (LoB) (3 ng/L) or limit of detection (LoD) (5 ng/L) of the assay have almost 100% negative predictive value (NPV) for acute myocardial infarction (AMI), particularly among patients without electrocardiograph (ECG) evidence of ischemia. We aimed to prospectively validate those findings. METHODS: We included adults presenting to the emergency department with suspected cardiac chest pain. Standard troponin T (cTnT) and hs-cTnT (both Roche Elecsys) were tested in samples drawn on arrival. The primary outcome was AMI, adjudicated by 2 investigators on the basis of clinical data and ≥12-h cTnT testing. We also evaluated diagnostic performance when AMI was readjudicated on the basis of hs-cTnT (≥12-h) concentrations. RESULTS: Of 463 patients included, 79 (17.1%) had AMI. Twenty-four patients (5.2%) had hs-cTnT concentrations below the LoB, although none had AMI. Ninety-six patients (20.7%) had hs-cTnT concentrations below the LoD, 1 of whom had AMI. Thus, diagnostic sensitivity was 98.7% (95% CI 87.5%-98.6%) and NPV was 99.0% (95% CI 94.3%-100.0%). Of the 17.3% (n = 80) patients with hs-cTnT below the LoD and no ECG ischemia, none had AMI. Thus, diagnostic sensitivity was 100.0% (95% CI 95.4%-100.0%) and NPV was 100.0% (95% CI 95.5%-100.0%). Sensitivity and NPV were maintained when AMI was readjudicated on the basis of hs-cTnT. CONCLUSIONS: Our findings confirm that patients with nonischemic ECG and undetectable hs-cTnT at presentation have a very low probability of AMI, although the proportion of patients affected was smaller than in previous research.
Authors: Andrea Fabbri; Cristina Bachetti; Filippo Ottani; Alice Morelli; Barbara Benazzi; Sergio Spiezia; Marco Cortigiani; Romolo Dorizzi; Allan S Jaffe; Marcello Galvani Journal: Intern Emerg Med Date: 2018-11-29 Impact factor: 3.397
Authors: Raphael R Bruno; Norbert Donner-Banzhoff; Wolfgang Söllner; Thomas Frieling; Christian Müller; Michael Christ Journal: Dtsch Arztebl Int Date: 2015-11-06 Impact factor: 5.594
Authors: Júlia Karády; Thomas Mayrhofer; Maros Ferencik; John T Nagurney; James E Udelson; Andreas A Kammerlander; Jerome L Fleg; W Frank Peacock; James L Januzzi; Wolfgang Koenig; Udo Hoffmann Journal: J Am Coll Cardiol Date: 2021-03-30 Impact factor: 24.094
Authors: Richard Body; Charles Boachie; Alex McConnachie; Simon Carley; Patricia Van Den Berg; Fiona E Lecky Journal: Emerg Med J Date: 2017-05-12 Impact factor: 2.740
Authors: Kevin King; Luanda P Grazette; Dina N Paltoo; John T McDevitt; Samuel K Sia; Paddy M Barrett; Fred S Apple; Paul A Gurbel; Ralph Weissleder; Hilary Leeds; Erin J Iturriaga; Anupama Rao; Bishow Adhikari; Patrice Desvigne-Nickens; Zorina S Galis; Peter Libby Journal: JACC Basic Transl Sci Date: 2016 Jan-Feb
Authors: Anoop S V Shah; Atul Anand; Yader Sandoval; Kuan Ken Lee; Stephen W Smith; Philip D Adamson; Andrew R Chapman; Timothy Langdon; Dennis Sandeman; Amar Vaswani; Fiona E Strachan; Amy Ferry; Alexandra G Stirzaker; Alan Reid; Alasdair J Gray; Paul O Collinson; David A McAllister; Fred S Apple; David E Newby; Nicholas L Mills Journal: Lancet Date: 2015-10-08 Impact factor: 202.731
Authors: Richard Body; Edward Carlton; Matthew Sperrin; Philip S Lewis; Gillian Burrows; Simon Carley; Garry McDowell; Iain Buchan; Kim Greaves; Kevin Mackway-Jones Journal: Emerg Med J Date: 2016-08-26 Impact factor: 2.740